trending Market Intelligence /marketintelligence/en/news-insights/trending/qWUkhQmdeGCvNr70c5ygCw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Delcath Systems updates reverse stock split ratio to 1-for-700

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Delcath Systems updates reverse stock split ratio to 1-for-700

Delcath Systems Inc. has increased the size of its reverse stock split to a ratio of 1-for-700.

The split will cut the New York-based company's estimated 1.4 billion issued and outstanding shares of common stock down to approximately 2.1 million. The move will take effect Dec. 24 and is larger than the company's previous ratio of 1-for-100.

American Stock Transfer & Trust Co. LLC is acting as the exchange agent and transfer agent for the reverse stock split.

Delcath Systems treats primary and metastatic liver cancers. Its investigational products include melphalan hydrochloride for injection, which is used to administer high-dose chemotherapy to the liver.